Nipro (8086) AI Stock Analysis

• Market Cap: ¥244.24B
• Dividend Yield: 2%
• Average Volume (3M): 446.75K
• Price to Earnings (P/E): 43.5
• Beta (1Y): 0.42
• Revenue Growth: 8.83%
• EPS Growth: -40.24%
• Country: JP
• Employees: 38,117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 20.06
• Shares Outstanding: 171,459,470
• 10 Day Avg. Volume: 400,570
• 30 Day Avg. Volume: 446,746
• PEG Ratio: -0.80
• Price to Book (P/B): 0.88
• Price to Sales (P/S): 0.34
• P/FCF Ratio: -27.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,300.73
• Price Target Upside: -13.43% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 62 Neutral
• Price Target: ¥1,593.00 ▲(6.02% Upside)

Nipro's overall stock score reflects a mix of financial strengths and weaknesses, with solid revenue growth but challenges in profitability and leverage. Technical indicators suggest potential short-term weakness, while a high P/E ratio indicates overvaluation. The dividend yield offers some support but may not offset valuation concerns.

Nipro Business Overview & Revenue Model

Company Description

Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. The company's Medical Device business develops, manufactures, and sells various disposable medical products comprising renal, intervention and anesthesiology, injection and infusion, dialysis, cardiopulmonary, diabetic, and cell cultures products; and sells artificial organ-related products, and generic and kit products. Its Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations. The company's Pharma Packaging business offers glass vials, ampoules, syringes, and cartridges; glass tubes; glass forming machinery; glass bulbs for vacuum flasks; and other parts of pharmaceutical packaging, such as rubber plugs. Its Other business provides thermostable enzymes for clinical chemistry. The company also offers business management services. Nipro Corporation serves customers in Japan, the Americas, Europe, and rest of Asia. The company was founded in 1947 and is headquartered in Osaka, Japan.

How the Company Makes Money

Nipro generates revenue through the sale of its medical devices and pharmaceutical products, catering primarily to hospitals, healthcare facilities, and distributors. Key revenue streams include the sale of dialysis equipment, IV therapy products, and blood management systems. Additionally, Nipro partners with various healthcare institutions and organizations to develop specialized products and solutions, which can lead to long-term contracts and steady income. The company also invests in research and development to introduce new technologies, ensuring a competitive edge in the healthcare market, and capitalizes on the growing demand for advanced medical treatments globally.

Nipro Financial Statement Overview

Summary

Nipro shows solid revenue growth and stable gross margins, but faces challenges in net profitability and high leverage. While operating cash flow is healthy, negative free cash flow indicates a need for improved capital management.

Income Statement

Nipro has demonstrated consistent revenue growth with a notable increase of 9.83% from 2024 to 2025. Gross profit margins have remained stable, reflecting strong cost management. However, the net profit margin has decreased due to a significant drop in net income, highlighting potential challenges in managing operating expenses or increased costs elsewhere.

Balance Sheet

The company's debt-to-equity ratio indicates high leverage, which could pose risks in economic downturns. Although total assets have increased, stockholder equity growth has not kept pace, resulting in a moderate equity ratio. Return on equity is low, suggesting challenges in generating efficient returns for shareholders.

Cash Flow

Nipro's free cash flow has shown improvement but remains negative, indicating ongoing challenges in generating surplus cash after capital expenditures. The operating cash flow to net income ratio is strong, suggesting that the company generates healthy operating cash relative to earnings, despite reduced net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	651.41B	644.59B	586.78B	545.20B	494.79B	455.56B
Gross Profit	195.14B	190.88B	171.32B	163.45B	149.27B	138.84B
EBITDA	94.16B	92.58B	84.62B	70.02B	73.54B	64.88B
Net Income	5.76B	5.11B	11.11B	4.57B	13.46B	14.21B
Balance Sheet
Total Assets	1.14T	1.18T	1.11T	1.03T	930.32B	854.40B
Cash, Cash Equivalents and Short-Term Investments	106.10B	106.67B	99.67B	89.68B	95.34B	90.27B
Total Debt	634.47B	636.87B	635.69B	605.93B	564.85B	545.28B
Total Liabilities	845.98B	864.77B	840.03B	785.23B	730.46B	680.35B
Stockholders Equity	238.21B	252.45B	232.66B	206.32B	185.24B	161.02B
Cash Flow
Free Cash Flow	0.00	-8.15B	-21.33B	-74.44B	-11.59B	14.91B
Operating Cash Flow	0.00	68.46B	72.94B	10.39B	68.21B	66.09B
Investing Cash Flow	0.00	-71.88B	-87.08B	-71.74B	-78.43B	-45.07B
Financing Cash Flow	0.00	5.38B	22.14B	43.08B	10.30B	-22.06B

Nipro Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1502.50
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8086, the sentiment is Negative. The current price of 1502.5 is below the 20-day moving average (MA) of 1507.08, below the 50-day MA of 1516.31, and above the 200-day MA of 1374.07, indicating a neutral trend. The MACD of 6.61 indicates Negative momentum. The RSI at 45.35 is Neutral, neither overbought nor oversold. The STOCH value of 58.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:8086.

Nipro Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7733	―	$2.07T	18.64	14.88%	1.05%	0.59%	557.87%
4543	―	¥3.67T	30.27	9.17%	1.13%	7.58%	6.74%
7716	―	€179.19B	34.68	4.39%	2.53%	10.98%	-76.45%
6869	―	$1.14T	23.83	10.48%	1.71%	5.09%	-9.10%
8086	―	¥244.24B	43.51	2.49%	2.00%	8.83%	-40.24%
7747	―	$628.13B	49.29	8.67%	1.02%	11.60%	-19.38%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Nipro Corporate Events

Nipro Corporation Announces Q1 2025 Financial Results with Mixed Performance

Nipro Corporation reported its consolidated financial results for the three months ended June 30, 2025, showing a 4.5% increase in net sales and a 24.6% rise in operating profit compared to the previous year. Despite these gains, the company experienced a significant decline in ordinary profit by 45.2%, reflecting challenges in its operations. The financial forecast for the fiscal year ending March 31, 2026, anticipates continued growth in net sales and operating profit, indicating a positive outlook for stakeholders.

The most recent analyst rating on (JP:8086) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on Nipro stock, see the JP:8086 Stock Forecast page.